The inhibitory effect of Ritodrine on human tubal activity in vivo.
D000284:Administration, Oral; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005187:Fallopian Tubes / Q000187:drug effects*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D009119:Muscle Contraction / Q000187:drug effects; D010627:Phenethylamines / Q000008:administration & dosage / Q000494:pharmacology*; D010636:Phenols / Q000008:administration & dosage / Q000494:pharmacology; D011412:Propanolamines / Q000008:administration & dosage / Q000494:pharmacology*; D011433:Propranolol / Q000494:pharmacology; D013566:Sympathomimetics / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D013997:Time Factors; D014599:Uterus / Q000187:drug effects
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D010627:Phenethylamines; D010636:Phenols; D011412:Propanolamines; D013566:Sympathomimetics; D011433:Propranolol